The Role of CSF in Chiari II Brain Malformation

Study Population and Methodology

This prospective case-control study will involve the collection of CSF samples from several groups, including:

• Newborns with open spina bifida undergoing postnatal surgery.
• Fetuses undergoing prenatal surgery for spina bifida.
• Newborns with hydrocephalus undergoing shunt surgery (control group).
• Infants undergoing spinal surgery for conditions unrelated to spina bifida (control group).
• Age-matched fetuses obtained from the Human Developmental Biology Resource (HDBR) as controls.
• Mouse models: This includes a genetic mouse model of spina bifida (Cdx2Cre x Pax3flox) and normal (wild-type) mice as controls

These samples will be analyzed using mass spectrometry-based proteomics to identify differences in protein composition and concentrations between the groups. Additionally, brain slices from human embryos and mouse models will be cultured in the presence of these CSF samples to assess the impact on neurogenesis and neuronal migration.

Expected Benefits The findings from this study are expected to provide new insights into the pathogenesis of Chiari II malformation and other associated brain anomalies in children with spina bifida. By understanding how CSF composition influences brain development, the study could pave the way for novel therapeutic strategies aimed at modifying CSF composition during early pregnancy. This could potentially prevent or mitigate the neurological impairments associated with spina bifida, ultimately improving the quality of life for affected individuals.

Impact on Clinical Practice and Policy Should the study confirm the hypothesis, it could lead to changes in clinical practices concerning the management of spina bifida and Chiari II malformation. For instance, it might inform the development of new prenatal treatments or interventions designed to normalize CSF composition before significant brain damage occurs4-6. This would represent a significant advancement in fetal surgery and pediatric neurosurgery, with the potential to influence guidelines and policies within the NHS and other healthcare systems globally.

Relation to Academic Qualification This study is being conducted as part of the Lewis Spitz PhD program at University College London (UCL) and Great Ormond Street Institute of Child Health (GOSH ICH). The research builds upon previous studies sponsored by UCL-ICH/GOSH, particularly those investigating the neurodevelopmental consequences of spina bifida and related congenital conditions.

Inclusion criteria

Newborns with Spina Bifida (Postnatal Closure)

• Diagnosed with open spina bifida (myelomeningocele).
• Scheduled for postnatal surgical closure of the spinal lesion at Great Ormond Street Hospital (GOSH).
• Age: Between 1 day to 1 year old.

Control Group 1 (Newborns with Hydrocephalus)

• Newborns scheduled for shunt surgery for hydrocephalus unrelated to spina bifida.
• Age and sex matched to the spina bifida newborns as closely as possible.
• Age: Between 1 day to 1 year old.

Control Group 2 (Infants with Spinal Conditions Unrelated to Spina Bifida)

• Infants undergoing paned spinal surgery for conditions such as spinal lipoma, fatty filum, tethered cord, etc.
• Age and sex matched to the spina bifida newborns as closely as possible.
• Age: Between 1 day to 1 year old. Fetuses with Spina Bifida (Prenatal Closure)
• Prenatal diagnosis of spina bifida (myelomeningocele) and scheduled for fetal surgery at UCLH.
• Reviewed by Mr Thompson at his outpatient clinic at GOSH
• Gestational age: Between 22 and 24 weeks.

Control Fetal Samples

• Aborted fetuses within the gestational age range of 22-24 weeks.
• Samples obtained through the Human Developmental Biology Resource (HDBR).

Mouse Models

• Genetic mouse model of spina bifida (Cdx2Cre x Pax3flox).
• At embryonic day (E)13.5 (end of the embryonic period) and E18.5 (just before birth)

Control Mouse Models

• Normal (wild-type) mice to serve as controls.
• Normal brain development
• At embryonic day (E)13.5 (end of the embryonic period) and E18.5 (just before birth)

Exclusion criteria

Newborns with Spina Bifida (Postnatal Closure)

• Newborns who have undergone previous surgical intervention.
• Presence of additional unrelated congenital anomalies that could affect cerebrospinal fluid (CSF) composition like meningitis or intraventricular bleeding
• Older than 1 year and 1 month of age.
• Parents refused to participate
• Native language different to English with no translation services available

Control Group 1 (Newborns with Hydrocephalus)

• Newborns with hydrocephalus caused by spina bifida.
• Presence of intraventricular infection or haemorrhage.
• Older than 1 year and 1 month of age.
• Parents refused to participate
• Native language different to English with no translation services available

Control Group 2 (Infants with Spinal Conditions Unrelated to Spina Bifida)

• Infants who were born with spina bifida
• Infants with coexisting conditions that could affect CSF composition like intraspinal tumours, empyema or haemorrhage.
• Older than 1 year and 1 month of age.
• Parents refused to participate
• Native language different to English with no translation services available

Fetuses with Spina Bifida (Prenatal Closure)

• Fetuses with additional major anomalies unrelated to spina bifida like diaphragmatic hernia.
• Gestational age outside the range of 22-24 weeks.
• Surgery performed by other neurosurgery team (not GOSH)
• Parents refused to participate
• Native language different to English with no translation services available

Control Fetal Samples

• Poorly preserved aborted fetuses not suitable for CSF collection.
• Gestational age outside the range 22-24 weeks.

Mouse Models

• Mice with any genetic modifications other than those specified for the spina bifida model.
• Mice with other congenital or acquired anomalies affecting the central nervous system.

Control Mouse Models

● Mice with any genetic modifications or health conditions that could influence the study's outcomes.